Identity
What is BPC-157?
A synthetic pentadecapeptide, also called body protection compound 157.

Research reference · Tissue Repair
BPC-157 is a synthetic 15-residue peptide studied mostly in rodent models of tissue and gut injury. In 2026 it moved from FDA’s restricted list to an HHS interim compounding policy, though it remains unapproved.
Published by Elevated Pharma ·
Identity
A synthetic pentadecapeptide, also called body protection compound 157.
Research context
The record is mainly preclinical. Human data are limited to small case series; two 2026 systematic reviews and an orthopaedic review conclude that controlled human evidence is lacking.
Evidence boundary
Preclinical findings do not establish human effectiveness or safety, and evidence for one compound does not transfer to a blend.
U.S. status · November 7, 2026
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention; nominated for ulcerative colitis). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
HHS published an enforcement-discretion policy covering BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 for licensed pharmacies and physicians. Comments close November 13, 2026.
Read the sourceA JAAOS review of BPC-157, thymosin beta-4 and TB-500 finds mostly preclinical evidence.
Read the sourceFDA’s Pharmacy Compounding Advisory Committee voted on seven peptides over July 23–24, recommending six and declining emideltide (DSIP).
Read the sourceFDA announced the removal of 12 peptide substances from its Category 2 compounding list, effective about April 22, 2026. Removal is not approval.
Read the sourceKey studies
Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.
Search all 224 PubMed records for BPC-157 · Counts and selections checked November 7, 2026.
Reference identifiers
Database identity describes the reference substance, not any specific material or lot.
Official & primary sources
Citation does not imply an Elevated Pharma partnership or endorsement.